$ILMN

Leckman Patricia sold $28K of ILMN

Leckman Patricia (SVP, Chief People Officer) sold 176 shares of ILLUMINA, INC. (ILMN) at $160.66 on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Leckman Patricia
Published Jun 4, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Neutral
high confidence
Mentioned
$ILMN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not constitute new company-specific fundamental news.

02

Market read

Routine 10b5-1 insider selling is generally not a standalone catalyst for ILMN price action.

03

What to watch

Insider sales can be driven by diversification, taxes, or scheduled liquidity needs; without additional filings (buys, large sales, or plan changes), signal strength is limited.

Relevance 6/10Novelty 2/10Timing: Filed after-hours (SEC EDGAR) for a sale dated 2026-06-02.

Background

SEC Form 4 reports insider transactions; a 10b5-1 plan indicates the trades were pre-scheduled to reduce timing-based trading concerns.

Company-level read

Ticker impact

$ILMNNeutralHigh confidence
Context

Illumina insider disclosure shows SVP Chief People Officer Patricia Leckman sold 176 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely noise unless paired with other catalysts.

Evidence & confidence

Form 4 details a small, planned sale (176 shares) with no accompanying corporate event, guidance change, or transaction terms beyond standard 10b5-1 disclosure.

Market effects

No clear read-through to biotech/genomics sector fundamentals from a routine planned insider sale.

None.

None.

Counterpoint

If insider sales cluster unusually around specific dates, traders sometimes treat it as a weak sentiment signal; this single small 10b5-1 sale alone is not enough.

Key entities

  • Illumina, Inc.

    Subject of the Form 4 insider transaction; SVP Chief People Officer sold shares under a 10b5-1 plan.

  • Patricia Leckman

    SVP, Chief People Officer; reported open-market sale of 176 shares on 2026-06-02.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNHighAI 8/10

Illumina Q2FY26 Results: Revenue up 9.5% to $1.16 billion

Illumina reported Q2 2026 revenue of $1.16B, up 9.5% YoY, driven by NovaSeq X demand and clinical consumables growth. Non-GAAP EPS rose 10% to $1.31. The company raised full-year guidance, projecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40. Management cited strong instrument placements and cost management despite rising expenses. Illumina repurchased 0.9M shares and holds $1.17B in cash. The stock has returned 13.26% annually over 20 years, outperforming the market by 3.84%.

$ILMNHighAI 8/10

Illumina Reports Q2 2026 Results: Full Earnings Call Transcript - Illumina (NASDAQ:ILMN)

Illumina (ILMN) reported Q2 2026 revenue growth of 9.5% YoY and EPS growth of 10%, driven by strong demand for NovaSeq X. The company raised its 2026 guidance, expecting full-year organic revenue growth over 5% and mid-teens growth in clinical consumables. Strategic initiatives include expanding multi-omics capabilities and strengthening the BioInsight platform. Management emphasized cost management and confidence in long-term targets.

$BELow

Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns?

Vanguard S&P 500 ETF (VOO) will add Bloom Energy (BE), Illumina (ILMN), and another company, while removing Molson Coors (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR). BE's product revenue surged 215% due to AI demand, and ILMN raised EPS guidance. The changes have minimal impact on VOO's returns, as the fund is heavily concentrated in megacap stocks.

$ILMNHigh

Illumina Stock Climbs As Analyst Upgrades Meet S&P 500 Boost

Illumina Inc. (ILMN) shares rose 7.15% on September 15, 2026, after UBS upgraded it to Buy with a $260 price target, and Argus raised its target to $235. The company's Q2 revenue was $1.16B, with EBITDA of $354M. Illumina is also being added to the S&P 500, effective September 21, 2026, which may drive further demand. The stock trades at a P/E ratio of 38 and P/S ratio of 6.9, reflecting its growth prospects. Analysts cite revenue reacceleration, margin expansion, and clinical demand as key driv